Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch

AstraZeneca and Merck’s Lynparza is the first in its ultra-competitive class of PARP inhibitors to post positive data in BRCA-mutated ovarian cancer patients who've just wrapped up an initial round of chemo. And it’s entering with a bang.